TrialBreast cancer research : BCR2023

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).

Sanne L de Haas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.